Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues

Forensic Toxicology

Volumn 33, Issue 2, 2015, Pages 355-366

  Banister, Samuel D ^a,b   Stuart, Jordyn ^c   Conroy, Trent ^b,d   Longworth, Mitchell ^b   Manohar, Madhura ^b   Beinat, Corinne ^a,b   Wilkinson, Shane M ^b   Kevin, Richard C ^b   Hibbs, David E ^b   Glass, Michelle ^e   Connor, Mark ^c   McGregor, Iain S ^b   Kassiou, Michael ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d EPFL   (Switzerland)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

RCS 2 C4; RCS 4 analogues; RCS 4 C4; Structure activity relationship; Synthetic cannabinoid

Indexed keywords

(1 BUTYL 1H INDOL 3 YL)(2 METHOXYPHENYL)METHANONE; (1 BUTYL 1H INDOL 3 YL)(3 METHOXYPHENYL)METHANONE; (1 BUTYL 1H INDOL 3 YL)(4 METHOXYPHENYL)METHANONE; (1 PENTYL 1H INDOL 3 YL)(2 METHOXYPHENYL)METHANONE; (1 PENTYL 1H INDOL 3 YL)(3 METHOXYPHENYL)METHANONE; (1 PENTYL 1H INDOL 3 YL)(4 METHOXYPHENYL)METHANONE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DESIGNER DRUG; UNCLASSIFIED DRUG; [(4 METHOXYPHENYL) 1 YL(1 PENTYL 1H INDOL 3 YL)METHANONE];

ANIMAL CELL; ARTICLE; BIOASSAY; CONTROLLED STUDY; CRYSTAL STRUCTURE; FLUOROMETRIC IMAGING PLATE READER MEMBRANE POTENTIAL ASSAY; FLUOROMETRY; GENETIC TRANSFECTION; IN VITRO STUDY; ISOMER; MASS FRAGMENTOGRAPHY; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; REGIOISOMER; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYNTHESIS; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION;

EID: 84937525412     PISSN: 18608965     EISSN: 18608973     Source Type: Journal    
DOI: 10.1007/s11419-015-0282-9     Document Type: Article

References (46)

1. Dresen S, Ferreiros N, Putz M, Westphal F, Zimmermann R, Auwärter V (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186–1194
2. Auwärter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837
3. 2. Pharmacol Rev 62:588–631
4. Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39:234–243
5. Mir A, Obafemi A, Young A, Kane C (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128:e1622–e1627
6. Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH (2011) Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 49:760–764
7. Simmons J, Cookman L, Kang C, Skinner C (2011) Three cases of “spice” exposure. Clin Toxicol 49:431–433
8. Schneir AB, Cullen J, Ly BT (2011) “Spice” girls: synthetic cannabinoid intoxication. J Emerg Med 40:296–299
9. Schneir A, Baumbacher T (2012) Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 8:62–64
10. Harris CR, Brown A (2013) Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 44:360–366
11. Uchiyama N, Shimokawa Y, Kawamura M, Kikura-Hanajiri R, Hakamatsuka T (2014) Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. Forensic Toxicol 32:266–281
12. European Monitoring Centre for Drugs and Drug Addictions (2014) European Drug Report 2014: trends and developments. Euro Surveill. doi:10.2810/32306
13. Wilkinson SM, Banister SD, Kassiou M (2015) Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust J Chem 68:4–8
14. Nakajima J, Takahashi M, Seto T, Kanai C, Suzuki J, Yoshida M, Hamano T (2011) Identification and quantitation of two benzoylindoles AM-694 and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone, and three cannabimimetic naphthoylindoles JWH-210, JWH-122, and JWH-019 as adulterants in illegal products obtained via the Internet. Forensic Toxicol 29:95–110
15. 35S]GTPγS binding assays. Forensic Toxicol 29:132–141
16. Logan BK, Reinhold LE, Xu A, Diamond FX (2012) Identification of synthetic cannabinoids in herbal incense blends in the United States. J Forensic Sci 57:1168–1180
17. Denooz R, Vanheugen JC, Frederich M, de Tullio P, Charlier C (2013) Identification and structural elucidation of four cannabimimetic compounds (RCS-4, AM-2201, JWH-203 and JWH-210) in seized products. J Anal Toxicol 37:56–63
18. Choi H, Heo S, Choe S, Yang W, Park Y, Kim E, Chung H, Lee J (2013) Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC–MS. Anal Bioanal Chem 405:3937–3944
19. Couch RAF, Madhavaram H (2012) Phenazepam and cannabinomimetics sold as herbal highs in New Zealand. Drug Test Anal 4:409–414
20. Zuba D, Byrska B (2013) Analysis of the prevalence and coexistence of synthetic cannabinoids in “herbal high” products in Poland. Forensic Toxicol 31:21–30
21. Simolka K, Lindigkeit R, Schiebel H-M, Papke U, Ernst L, Beuerle T (2012) Analysis of synthetic cannabinoids in “spice-like” herbal highs: snapshot of the German market in summer 2011. Anal Bioanal Chem 404:157–171
22. Park Y, Lee C, Lee H, Pyo J, Jo J, Lee J, Choi H, Kim S, Hong RS, Park Y, Hwang BY, Choe S, Jung JH (2013) Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-methoxybenzoyl)indole. Forensic Toxicol 31:187–196
23. Chung H, Choi H, Heo S, Kim E, Lee J (2014) Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013. Forensic Toxicol 32:82–88
24. Hutter M, Broecker S, Kneisel S, Auwärter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC–MS/MS techniques. J Mass Spectrom 47:54–65
25. Kavanagh P, Grigoryev A, Melnik A, Simonov A (2012) The identification of the urinary metabolites of 3-(4-methoxybenzoyl)-1-pentylindole (RCS-4), a novel cannabimimetic, by gas chromatography–mass spectrometry. J Anal Toxicol 36:303–311
26. Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Huestis MA (2014) Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF–MS. Bioanalysis 6:1471–1485
27. Scheidweiler KB, Huestis MA (2014) Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography–tandem mass spectrometry. J Chromatogr A 1327:105–117
28. Hutter M, Kneisel S, Auwärter V, Neukamm MA (2012) Determination of 22 synthetic cannabinoids in human hair by liquid chromatography–tandem mass spectrometry. J Chromatogr B 903:95–101
29. Sundstroem M, Pelander A, Angerer V, Hutter M, Kneisel S, Ojanperae I (2013) A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC–HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal Bioanal Chem 405:8463–8474
30. Wohlfarth A, Scheidweiler KB, Chen X, H-f Liu, Huestis MA (2013) Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC–MS/MS and library search. Anal Chem 85:3730–3738
31. Kronstrand R, Brinkhagen L, Birath-Karlsson C, Roman M, Josefsson M (2014) LC–QTOF–MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine. Anal Bioanal Chem 406:3599–3609
32. Kneisel S, Auwärter V (2012) Analysis of 30 synthetic cannabinoids in serum by liquid chromatography–electrospray ionization tandem mass spectrometry after liquid–liquid extraction. J Mass Spectrom 47:825–835
33. Kneisel S, Speck M, Moosmann B, Corneillie TM, Butlin NG, Auwärter V (2013) LC/ESI–MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows. Anal Bioanal Chem 405:4691–4706
34. Kneisel S, Auwärter V, Kempf J (2013) Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography–electrospray ionization tandem mass spectrometry. Drug Test Anal 5:657–669
35. Ammann J, McLaren JM, Gerostamoulos D, Beyer J (2012) Detection and quantification of new designer drugs in human blood: part 1—synthetic cannabinoids. J Anal Toxicol 36:372–380
36. Ito Y, Kobayashi K, Seko N, Saegusa T (1984) Indole syntheses utilizing o-methylphenyl isocyanides. Bull Chem Soc Jpn 57:73–84
37. Blaazer AR, Lange JHM, van der Neut MAW, Mulder A, den Boon FS, Werkman TR, Kruse CG, Wadman WJ (2011) Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure–activity relationships, physicochemical properties and biological activity. Eur J Med Chem 46:5086–5098
38. Bruker (2011) Apex2 suite of programs. Bruker AXS Inc., Madison
39. Sheldrick GM (2008) A short history of SHELX. Acta Crystallogr A 64:112–122
40. Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, Brooker L, Goebel C, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (2013) The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci 4:1081–1092
41. Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (2015) The effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci. doi:10.1021/acschemneuro.5b00107
42. Knapman A, Santiago M, Du YP, Bennallack PR, Christie MJ, Connor M (2013) A continuous, fluorescence-based assay of µ-opioid receptor activation in AtT-20 cells. J Biomol Screen 18:269–276
43. Okauchi T, Itonaga M, Minami T, Owa T, Kitoh K, Yoshino H (2000) A general method for acylation of indoles at the 3-position with acyl chlorides in the presence of dialkylaluminum chloride. Org Lett 2:1485–1487
44. Grimsey NL, Graham ES, Dragunow M, Glass M (2010) Cannabinoid receptor 1 trafficking and the role of the intracellular pool: implications for therapeutics. Biochem Pharmacol 80:1050–1062
45. 2 cannabinoid receptor activity. J Med Chem 51:1904–1912
46. 2 cannabinoid receptor activity. J Med Chem 53:295–315